Matthew Streetly


Consultant haematologist


Matthew Streetly, B.Med.Sci, BM, BS; MRCP(UK), FRCPath, PhD, has been a consultant at our hospital since 2008. He is the clinical lead for myeloma/plasma cell disorders and a member of the haemato-oncology inpatient attending team looking after inpatients with myeloma, lymphoma and leukaemia.

Matthew has a special interest in the use of novel therapies for patients with myeloma and is the principal investigator on multiple clinical trials.

Matthew is a member of the UK myeloma forum guidelines writing group and a special trustee of the British Society of Haematology. He has published widely on myeloma and related disorders and is an invited speaker at national and international meetings.

Education and training

  • Undergraduate training – University of Nottingham
  • Postgraduate haematology training – Guy's and St Thomas’
  • PhD investigating novel compounds in myeloma / myeloma apoptosis – Queen Mary, University of London

Research interests

  • Clinical trials for novel therapies for myeloma
  • Myeloma diagnostics and biomarkers

Last updated: April 2022

Is this page useful?